Thank you for attending Kaiser Permanente’s Institute for Health Policy Forum. Please use this webpage to find event materials and information.
9:00 a.m.
Meet & Greet / Coffee
9:30 a.m.
Welcome
Cecilia Oregón, MPP, MPH
Executive Director, Institute for Health Policy
Kaiser Permanente
Anthony Barrueta, JD
Senior Vice President, Government Relations
Kaiser Permanente
9:45 a.m.
The root causes of high U.S. drug prices
Moderator:
Dan Gorenstein
Founder and Executive Editor
Tradeoffs Podcast
Speakers:
Tahir Amin, LL.B., Dip. LP.
CEO and Co-Founder
I-MAK
Leigh Purvis, MPA
Prescription Drug Policy Principal
AARP Public Policy Institute
Kristi Martin, MA, MPA
President, Highway 136 Consulting
Director, Camber Collective
11:00 a.m.
What influences drug prescribing & utilization?
Moderator:
Krysten Joyce, MPH
Senior Policy Consultant, Institute for Health Policy
Kaiser Permanente
Speakers:
Jerry Avorn, MD (recorded remarks)
Professor of Medicine, Harvard Medical School
Chief Emeritus, Division of Pharmacoepidemiology and Pharmacoeconomics
Co-Director, Program on Regulation, Therapeutics, and Law
Adriane Fugh-Berman, MD
Director, PharmedOut
Professor, Georgetown University
Kim Le, PharmD
Interim Senior Vice President & Chief Pharmacy Officer
National Pharmacy Services, Kaiser Permanente
Carly Robinson, PharmD, FAMCP
Vice President & Chief Pharmacy Officer, Moda Health
President, The Academy of Managed Care Pharmacy
12:00 p.m.
Networking Lunch
12:45 p.m.
The current state of play: A conversation with experts in policy and economics
Moderator:
Lauren Aronson
Executive Director, The Campaign for Sustainable Drug Pricing (CSRxP)
Partner, Mehlman Consulting
Speakers:
Anna Kaltenboeck, MA, MBA
President
Verdant Research
Conor Sheehey, MAT
Director, Leavitt Partners
Former Senior Health Counsel, U.S. Senate Committee on Finance
Polly Webster, JD, MPH
Senior Health Counsel
U.S. Senate Committee on Finance
Marta Wosińska, PhD
Senior Fellow, Center on Health Policy
The Brookings Institution
2:00 p.m.
Cecilia Oregón, MPP, MPH
Executive Director, Institute for Health Policy
Kaiser Permanente
2:15 p.m.
Adjourn
To learn more about drug pricing policy, check out Tradeoffs’ three-part series on the generic drug industry, Race to the Bottom, and their full archive of prescription drug reporting.
To learn more about prescription drug approval, value, safety and costs check out Dr. Jerry Avorn’s new book Rethinking Medications
Other publications from the Kaiser Permanente Institute of Health Policy include:
How is Kaiser Permanente different from other health plans when it comes to prescription drugs?
Biosimilars at Kaiser Permanente: Lessons in successfully reducing spending on prescription drugs
Evolving nature of evidence required by FDA to approve new drugs
Health Affairs Forefront: Restoring Provider Confidence In FDA-Approved Drugs
Health Affairs Forefront: How Lawmakers Can Achieve Savings From Biosimilars: Lessons From Kaiser Permanente
Health Affairs Forefront: The Real Reasons Drug Prices Are So High
By attending today’s event, you are agreeing to the following policies: